Taysha Gene TherapiesTSHA
TSHA
About: Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
Employees: 73
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1,957% more call options, than puts
Call options by funds: $144K | Put options by funds: $7K
100% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 2 (+1) [Q1 2025]
23% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 31
0.18% less ownership
Funds ownership: 81.53% [Q4 2024] → 81.35% (-0.18%) [Q1 2025]
8% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 25
2% less funds holding
Funds holding: 128 [Q4 2024] → 125 (-3) [Q1 2025]
20% less capital invested
Capital invested by funds: $289M [Q4 2024] → $232M (-$57.2M) [Q1 2025]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
111%
upside
Avg. target
$8.40
195%
upside
High target
$11
286%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
B of A Securities Tazeen Ahmad | 181%upside $8 | Buy Initiated | 11 Jul 2025 |
Needham Gil Blum | 181%upside $8 | Buy Reiterated | 1 Jul 2025 |
Canaccord Genuity Whitney Ijem | 286%upside $11 | Buy Maintained | 3 Jun 2025 |
JMP Securities Silvan Tuerkcan | 111%upside $6 | Market Outperform Maintained | 29 May 2025 |
Chardan Capital Geulah Livshits | 216%upside $9 | Buy Maintained | 29 May 2025 |
Financial journalist opinion
Positive
Zacks Investment Research
1 week ago
Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade
Taysha Gene Therapies (TSHA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
GlobeNewsWire
3 weeks ago
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, July 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on July 1, 2025, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, options to purchase 30,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 month ago
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, June 06, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 2, 2025, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, options to purchase 401,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 month ago
Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program
Recently disclosed clinical cohort data from high (1x10 15 total vg) and low dose (5.7x10 14 total vg) TSHA-102 from REVEAL adolescent/adult and pediatric Phase 1/2 trials
Positive
Benzinga
2 months ago
Why Is Taysha Gene Therapies Stock Trading Higher On Thursday?
Taysha Gene Therapies Inc. TSHA on Wednesday announced details of its planned pivotal Part B trial design for TSHA-102 following written alignment from the U.S. Food and Drug Administration (FDA).
Neutral
GlobeNewsWire
2 months ago
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 46,868,687 shares of its common stock at a price to the public of $2.75 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 25,858,586 shares of its common stock at an offering price of $2.749 per pre-funded warrant, in each case before underwriting discounts and commissions. All of the securities are being offered by Taysha. In addition, Taysha has granted the underwriters a 30-day option to purchase up to an additional 10,909,090 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering to Taysha are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about May 30, 2025, subject to customary closing conditions.
Neutral
GlobeNewsWire
2 months ago
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. All of the securities will be offered by Taysha. Taysha also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering under the same terms and conditions (including shares underlying the pre-funded warrants). The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
Neutral
GlobeNewsWire
2 months ago
Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102
Natural history data analysis established patients ≥ six years of age are in developmental plateau, with a ~0% likelihood of gaining/regaining developmental milestones across the core functional domains of Rett syndrome
Neutral
Seeking Alpha
2 months ago
Taysha Gene Therapies, Inc. (TSHA) Q1 2025 Earnings Call Transcript
Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Hayleigh Collins - Senior Director, Corporate Communications and Investor Relations Sean P. Nolan - Chief Executive Officer Sukumar Nagendran - President and Head of R&D Kamran Alam - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Gil Blum - Needham and Company Maury Raycroft - Jefferies Yanan Zhu - Wells Fargo Biren Amin - Piper Sandler Whitney Ijem - Canaccord Genuity Jack Allen - Baird Joon Lee - Truist Securities Silvan Tuerkcan - Citizens Malcolm Hoffman - BMO Capital Markets Operator Greetings, and welcome to the Taysha Gene Therapies First Quarter 2025 Earnings Call.
Neutral
Zacks Investment Research
2 months ago
Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates
Taysha Gene Therapies, Inc. (TSHA) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.10 per share a year ago.
Charts implemented using Lightweight Charts™